Target Protein Drug Testing Services: Comprehensive Analysis for Biologics & Targeted Therapies

As an independent third-party analytical service provider, we offer comprehensive testing for target protein drugs – including monoclonal antibodies (mAbs), antibody‑drug conjugates (ADCs), bispecific antibodies, fusion proteins, recombinant cytokines, and other protein‑based therapeutics. Target protein drugs represent the fastest‑growing segment of the biopharmaceutical industry, with applications in oncology, autoimmune diseases, infectious diseases, and metabolic disorders. Rigorous physicochemical, functional, and safety characterization is essential for product release, stability studies, comparability assessments, and regulatory submissions. Our accredited laboratory follows international standards (ICH Q6B, USP <129>, Ph. Eur. 2.2, FDA guidance for biologics) using state‑of‑the‑art analytical platforms (LC‑MS, HPLC, CE, SPR, ELISA, cell‑based bioassays). This article outlines our target protein drug testing capabilities – including scope, key test items, and standard methods – to help biopharmaceutical companies, CROs, and regulatory agencies ensure product quality, safety, and efficacy.

1. Our Testing Scope for Target Protein Drugs

We cover all major classes of protein therapeutics and analytical attributes:

By product class: Monoclonal antibodies (mAbs – IgG1, IgG2, IgG4, bispecific, Fc‑fusion); Antibody‑drug conjugates (ADCs – payload distribution, drug‑to‑antibody ratio – DAR); Recombinant proteins (cytokines – IL‑2, IFN, EPO; growth factors – VEGF, FGF; enzymes – DNase, glucocerebrosidase); Fusion proteins (Fc‑fusions, albumin fusions, ligand‑traps); Peptide therapeutics (by arrangement); Biosimilars and biobetters.

By test category: Physicochemical properties (identity, purity, molecular weight, charge variants, glycosylation, aggregation); Structural characterization (primary sequence, disulfide bond mapping, post‑translational modifications – PTMs); Binding activity (antigen binding by ELISA, SPR, BLI; Fc receptor binding – FcγR, FcRn); Functional activity (cell‑based bioassays – neutralization, proliferation, cytotoxicity, reporter gene assays); Product‑related impurities (aggregates, fragments, host cell proteins – HCP, host cell DNA); Process‑related impurities (residual Protein A, detergents, endotoxins); Stability studies (forced degradation, real‑time/accelerated stability, aggregation, fragmentation, deamidation, oxidation).

By analytical platform: Liquid chromatography (SEC – size exclusion, IEX – ion exchange, HIC – hydrophobic interaction, RP – reversed phase); Mass spectrometry (intact mass, peptide mapping, glycan analysis, disulfide linkage); Capillary electrophoresis (CE‑SDS, cIEF – imaged capillary isoelectric focusing); Surface plasmon resonance (SPR – Biacore); Bio‑layer interferometry (BLI – Octet); ELISA (direct/indirect/sandwich); Cell‑based potency assays (reporter gene, proliferation, cytotoxicity, ADCC, CDC); Endotoxin and bioburden testing.

By regulatory standard: ICH Q6B (Test procedures and acceptance criteria for biotechnological/biological products); USP <129> (Recombinant therapeutic monoclonal antibodies); Ph. Eur. 2.2 (General methods for biologics); FDA Guidance for Industry on mAb quality; China NMPA guidelines for biosimilars.

2. Key Test Items & Measurements We Perform

Our target protein drug testing services are organized into five key quality attribute categories as recommended by ICH Q6B.

2.1 Identity & Purity

These tests confirm that the product is the intended molecule and assess product‑related impurities.

Peptide mapping (LC‑MS/MS) – Tryptic digest followed by high‑resolution mass spectrometry to confirm the primary sequence (100% coverage). Identifies sequence variants, mis‑incorporations, and post‑translational modifications (deamidation, oxidation, glycation).

Intact mass analysis (LC‑MS) – Measures the accurate mass of the intact protein (light chain, heavy chain, intact mAb). Confirms correct molecular weight and detects glycoforms, C‑terminal lysine processing, and fragmentation.

Disulfide bond mapping – Partial reduction and alkylation, followed by LC‑MS/MS to map inter‑chain and intra‑chain disulfide bridges. Identifies scrambled or mismatched disulfide bonds (which can affect stability and activity).

N‑glycan profiling – Released glycans (PNGase F) are labeled (2‑AB) and analyzed by HILIC‑UPLC‑FLR. Reports percentages of high‑mannose (Man5, Man6, Man7, Man8, Man9), complex (G0, G0F, G1, G1F, G2F), hybrid, afucosylated, and galactosylated species. Glycosylation impacts effector function (ADCC, CDC) and pharmacokinetics.

Size exclusion chromatography (SEC‑HPLC) – Quantifies high molecular weight (HMW) aggregates (dimer, trimer, higher‑order) and low molecular weight (LMW) fragments (clipped species). Aggregates are immunogenic; fragments reduce potency. Reporting limit: ≥0.1%.

Capillary electrophoresis (CE‑SDS) – Reduced (with DTT) and non‑reduced conditions. Purity is expressed as % main peak, % fragments, % aggregates. Provides higher resolution than SDS‑PAGE for quantitating product‑related impurities.

Imaged capillary isoelectric focusing (icIEF) – Determines charge variant profile (acidic variants – deamidation, sialylation; basic variants – C‑terminal lysine, succinimide). Charge heterogeneity can affect potency and PK.

Host cell protein (HCP) ELISA – Uses a process‑specific or generic ELISA (e.g., CHO‑HCP, E. coli‑HCP) to quantify residual host cell proteins. LOD typically ≤1 ng/mg. High HCP can trigger immunogenicity.

Residual Protein A ELISA – For mAbs purified with Protein A affinity chromatography. Quantifies leached Protein A in the final drug substance. LOD ≤1 ppm.

2.2 Binding Activity (Affinity & Avidity)

These tests evaluate the ability of the drug to bind to its molecular target(s).

Target binding ELISA – Direct or competitive ELISA using immobilized antigen (recombinant target protein or cell‑expressed antigen). Reports EC₅₀ (concentration giving 50% maximal binding) or relative binding versus reference standard. For ADCs, also measure binding after conjugation.

Surface plasmon resonance (SPR – Biacore) – Real‑time label‑free binding kinetics. Reports association rate (kₐ, M⁻¹s⁻¹), dissociation rate (k_d, s⁻¹), and equilibrium dissociation constant (K_D, M). Essential for characterizing affinity maturation, off‑rate sorting, and epitope binning.

Bio‑layer interferometry (BLI – Octet) – Similar to SPR but with simpler optics, higher throughput. Suitable for screening multiple binders, concentration determination, and ligand binding.

Epitope binning – Competitive binding assay using two antibodies on the same antigen. Determines whether different mAbs compete for the same or overlapping epitopes – critical for selecting antibody pairs for sandwich assays or combination therapy.

Fc receptor binding (FcγR, FcRn) – SPR or ELISA to measure binding to human FcγRIIIa (CD16a) for ADCC potency, FcγRIIb for inhibitory signaling, and FcRn for pH‑dependent recycling (affects half‑life). Fc glycoengineering (afucosylation) increases FcγRIIIa binding.

2.3 Functional Activity (Potency & Bioactivity)

These cell‑based assays measure the biological activity of the drug in a living cell system.

Neutralization bioassay (neutralizing antibody) – For drugs that block a ligand‑receptor interaction (e.g., anti‑IL‑6R, anti‑PD‑1). Cells expressing the receptor are treated with ligand ± test antibody; a readout (e.g., reporter gene, cytokine production) is measured. The half‑maximal inhibitory concentration (IC₅₀) is reported.

ADCC (antibody‑dependent cell‑mediated cytotoxicity) – Uses effector cells (PBMCs, NK‑92 cells) and target cells expressing the antigen. Lysis is measured by LDH release, calcein release, or flow cytometry. Relative potency vs. reference standard is expressed as EC₅₀ or % activity.

CDC (complement‑dependent cytotoxicity) – Target cells + antibody + complement (human or rabbit). Lysis measured by LDH or Alamar Blue. Important for mAbs targeting cell‑surface antigens (e.g., rituximab, ofatumumab).

Apoptosis induction – For agonistic antibodies (e.g., anti‑DR5, anti‑CD40). Annexin V/PI staining and caspase activation measured by flow cytometry or HCS.

Proliferation / anti‑proliferation assay – For growth factors or anti‑mitogenic antibodies. Cells are treated, and viable cell count is measured by MTT, CellTiter‑Glo, or direct counting.

Reporter gene assay (RGA) – Engineered cell line with a luciferase reporter under a pathway‑specific promoter (e.g., NF‑κB for anti‑TNF, STAT for interferon). High throughput, excellent precision. Often used as a potency release assay.

2.4 Stability & Degradation Profiling

These studies assess the stability of the drug under recommended storage conditions and accelerated stress.

Real‑time stability – Storage at 2‑8°C (for liquid formulations) or -20°C (frozen). Tested at 0, 3, 6, 9, 12, 18, 24 months. Attributes: purity (SEC, CE‑SDS), charge variants (icIEF), activity (binding ELISA or bioassay), color/clarity, pH, sub‑visible particles.

Accelerated stability – 25°C/60% RH or 37°C for up to 6 months. Predicts short‑term temperature excursions.

Forced degradation (stress studies) – Expose to heat (40‑60°C), light (1.2 million lux·h), oxidation (2% H₂O₂ or 2,2’‑azobis(2‑amidinopropane) dihydrochloride – AAPH), acidic/alkaline pH (pH 3, pH 10), and freeze‑thaw (5 cycles). Degradation products are characterized by SEC, CE‑SDS, icIEF, and LC‑MS to identify chemical modifications (deamidation, oxidation, isomerization).

2.5 Product‑Specific & Advanced Characterisation

Drug‑to‑antibody ratio (DAR) – For ADCs, measured by hydrophobic interaction chromatography (HIC), LC‑MS (intact mass), or UV‑Vis (absorbance ratio at 280 and 250 nm). DAR distribution affects efficacy and safety.

Payload distribution (ADCs) – LC‑MS/MS quantification of released payload (e.g., MMAE, DM1, SN‑38) in ADC and in plasma.

Bispecific antibody assembly – LC‑MS and native MS to confirm correct pairing of two different heavy/light chains. Detects mispaired species (homodimers, half‑antibodies).

Sub‑visible particles – Light obscuration (HIAC) and micro‑flow imaging (MFI) to quantify ≥10 μm and ≥25 μm particles per container. USP <787> and <788>.

Viscosity and osmolality – For high‑concentration mAb formulations (≥100 mg/mL). Measured by rheometer and freezing point depression.

3. Standard Test Methods We Apply

All tests are performed according to pharmacopoeial or ICH‑aligned methods. Our laboratory is ISO/IEC 17025 accredited (for select methods) and follows GMP principles.

3.1 Physical‑Chemical Methods

SEC‑HPLC: USP <129>, USP <621>; Ph. Eur. 2.2.29.
CE‑SDS: USP <129> (method 4), Ph. Eur. 2.2.56.
icIEF: USP <129> (method 5), Ph. Eur. 2.2.58.
Glycan profiling (HILIC‑UPLC‑FLR): USP <129> (method 7).
Mass spectrometry (intact mass, peptide mapping): ICH Q6B, Ph. Eur. 2.2.30.
Sub‑visible particles: USP <787> (proteinaceous), USP <788> (light obscuration), USP <789> (micro‑flow imaging).

3.2 Binding & Activity Methods

ELISA (binding, potency): USP <1103> (biological assays).
Surface plasmon resonance (SPR): USP <129> (optional).
Reporter gene assay (RGA): FDA guidance for potency assays.
ADCC reporter bioassay (Promega, etc.): accepted by regulatory authorities for potency release.
Neutralization assay (IC₅₀ determination): WHO guidelines.

4. Why Choose Our Third‑Party Target Protein Drug Testing Services?

As an independent laboratory, we provide unbiased, accurate, and regulatorily compliant data. Our strengths include:

ISO/IEC 17025 accreditation – We operate under a quality system aligned with GMP, and our testing data can be used for IND, BLA, and biosimilar comparability submissions.

State‑of‑the‑art equipment – LC‑MS (Thermo Q‑Exactive, Sciex TripleTOF), HPLC/UPLC (Agilent, Waters), CE (Beckman PA800 Plus), icIEF (ProteinSimple iCE3), SPR (Biacore 8K+), Octet BLI, cell‑based assay platforms (EnVision, FLUOstar Omega), and high‑content imaging (Molecular Devices ImageXpress).

Full comparability support – For biosimilars, we provide head‑to‑head analytical similarity testing (tiered approach: primary structure, higher order structure, purity, charge variants, glycosylation, binding, potency).

Forced degradation expertise – We design stress studies to identify degradation pathways and establish stability‑indicating methods.

Fast turnaround – Routine purity (SEC, CE‑SDS) results in 3‑5 business days; peptide mapping and glycan profiling in 2‑3 weeks; potency assays in 2‑4 weeks; stability studies scheduled over months.

Detailed reporting – Includes chromatograms, electropherograms, MS spectra, binding curves, IC₅₀/EC₅₀ values, and comparison to reference standard.

Confidentiality – Full protection of proprietary sequences, cell lines, and manufacturing data.

Consultative support – Our biophysical and biological characterization experts assist in setting specifications, designing stability protocols, and interpreting potency discrepancies.

Whether you need to release a clinical batch of a monoclonal antibody, characterize a bispecific molecule for IND filing, demonstrate biosimilarity to a reference product, or investigate an unexpected aggregation issue, our target protein drug testing experts are ready to deliver reliable, actionable results.

Get Started with Your Target Protein Drug Testing Project

Contact our team with your product class (mAb, ADC, fusion protein, biosimilar), required test attributes (identity, purity, potency, stability, comparability), and applicable regulatory guidelines (ICH, USP, FDA, NMPA). We will provide a detailed quotation, sample submission guidelines (sterile, low protein binding tubes, appropriate buffer), and a testing schedule. Let us help you ensure the quality, safety, and efficacy of your protein therapeutics.

This article provides an overview of our target protein drug testing capabilities. For specific test methods, sample quantity, and pricing, please request a tailored service proposal.